PFE vs JNJ
PFE and JNJ side by side — valuation & fundamentals (public data).
Key statistics
| Metric | PFEPfizer Inc. | JNJJohnson & Johnson |
|---|---|---|
| Market cap | $143.65B | $644.21B |
| P/E (TTM) | 19.2 | 31.0 |
| P/B | 1.59 | 7.58 |
| P/S | 2.3x | 6.8x |
| Dividend yield | 6.80% | 1.92% |
| Revenue | $63.31B(TTM) | $97.93B(TTM) |
| Revenue growth (YoY) | -1.6% | 6.0% |
| Net income | $7.49B(TTM) | $21.04B(TTM) |
| Earnings growth (YoY) | -3.2% | 90.6% |
| EPS, diluted | $1.31(TTM) | $8.62(TTM) |
| EBIT margin | 16.3% | 22.9% |
| ROE | 8.6% | 31.5% |
| ROIC | 6.7% | 16.1% |
| Piotroski F | — | 6/9 |
| 1y total return | +11.0% | +61.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: PFE vs JNJ
| Metric | PFE | JNJ |
|---|---|---|
| End value | $13.6K | $32.7K |
| Total return | +35.5% | +227.0% |
| CAGR | +3.0% | +12.1% |
| Volatility | 23.9% | 18.5% |
| Sharpe | 0.08 | 0.50 |
| Sortino | 0.11 | 0.72 |
| Max drawdown | -59.0% | -27.4% |
Based on 2600 common trading days, 2016-03-28 → 2026-07-29 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)